The Food and Drug Administration (FDA) approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications. The Collaborative on REMS Education (CO*RE), a multidisciplinary collaboration of 10 Partners and three cooperating organizations, have designed a core curriculum based on needs assessment, practice gaps, clinical competencies, learner self-assessment, with shared tools, resources, and outcomes to meet the requirements of the FDA REMS Blueprint.
- Describe appropriate patient assessment for treatment with ER/LA opioid analgesics, evaluating risks and potential benefits of ER/LA therapy, as well as possible misuse
- Apply proper methods to initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, applying best practices including accurate dosing and conversion techniques as well as appropriate discontinuation strategies.
- Demonstrate accurate knowledge about how to manage ongoing therapy with ER/LA opioid analgesics, properly use evidence based tools while assessing for adverse effects.
- Employ methods to counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal.
- Review/assess general and product-specific drug information concerning ER/LA opioid analgesics, identifying potential adverse effects of ER/LA opioids.